Clinical trials: Relapsed ALL, Adult
Diffuse Large B Cell Lymphoma (DLBCL)
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
The purpose of this study is to evaluate the the efficacy and safety in the real-world settings of glofitamab among Chinese R/R DLBCL participants.
- Trial name
- NCT06656234
- Testing
- Glofitamab, Obinutuzumab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Ruijin Hospital
Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant
This phase I/II trial studies the side effects and best dose of donor lymphocyte infusions when given together with daratumumab and to see how well they work in treating participants with acute myeloid leukemia that has come back…
- Conditions
- Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
- Trial name
- NCT03537599
- Testing
- Daratumumab, Donor Lymphocyte Infusion, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sumithira Vasu
Refractory AML, Relapsed Adult AML
Tislelizumab with Azacitidine in the Treatment of R/R AML
Acute myeloid leukemia(AML) is a clonal hematological malignancy. 50%-90% adult AML patients can achieve complete remission(CR) after standard induction chemotherapy,but 10%-25% patients cannot achieve CR, which is called…
- Trial name
- NCT06586099
- Testing
- Aza, tislelizumab
- Where
- China
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia, Lymphoma
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
RATIONALE: Giving low-dose total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00996359
- Testing
- Irradiated haploidentical allogeneic lymphocytes, total-body irradiation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Chronic Hepatitis C Virus Infection
Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers
The study will be a randomized, double blind, placebo controlled, dose rising study in Interferon alpha (IFN-alpha) non-responder HCV infected patients or HCV patients who have relapsed following IFN-alpha therapy.
- Trial name
- NCT00255359
- Testing
- XTL-2125
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Hadassah Medical Organization
Anemia, Chronic Myeloproliferative Disorders
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy, such as busulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Anemia, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00301912
- Testing
- filgrastim, busulfan, fludarabine phosphate
- Where
- United States
- Sponsor
- University of California, San Francisco
Myelodysplastic Syndromes
A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)
This study will be used to determine the maximum tolerated dose of oral clofarabine when administered daily for 14 consecutive days repeated every 21 days.
- Trial name
- NCT00750334
- Testing
- clofarabine
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Genzyme, a Sanofi Company
B-cell Adult Acute Lymphoblastic Leukemia (ALL), Ph-positive Adult Acute Lymphoblastic Leukemia (ALL)
Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
This study evaluates the value of bortezomib in combination with specified chemotherapies for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia (ALL), Ph-positive Adult Acute Lymphoblastic Leukemia (ALL), Recurrent Adult Acute Lymphoblastic Leukemia (ALL), T-cell Adult Acute Lymphoblastic Leukemia (ALL)
- Trial name
- NCT01769209
- Testing
- Bortezomib, Doxorubicin hydrochloride (HCl), PEG-Asparaginase
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stanford University
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia Relapse in Sweden 2003-2007
A minority of patients with adult acute lymphoblastic leukemia (ALL) relapse are rescued. The aim of this population-based study was to assess the results of reinduction treatment and allogeneic stem cell transplantation (SCT) in…
- Trial name
- NCT01470924
- Where
- Sweden
- Volunteers
- 76 people
- Sponsor
- Region Örebro County
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in patients who have relapsed or refractory…
- Trial name
- NCT00036946
- Testing
- ziv-aflibercept
- Where
- United States
- Sponsor
- Regeneron Pharmaceuticals
Lymphoma
Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma
RATIONALE: Combinations of biological substances in alefacept may be able to carry cancer-killing substances directly to cancer cells.
- Trial name
- NCT00438802
- Testing
- Alefacept
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Mayo Clinic
Lymphoma
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous peripheral stem cell transplantation may allow the doctor to give…
- Trial name
- NCT00003957
- Testing
- filgrastim, recombinant human stem cell factor, cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fox Chase Cancer Center
Cancer
Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation
RATIONALE: Captopril may protect the lungs from the side effects of bone marrow or stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of captopril to lessen the side effects in patients…
- Trial name
- NCT00004230
- Testing
- captopril, cyclophosphamide, autologous bone marrow transplantation
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Northwestern University
Acute Lymphoblastic Leukemia
Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
This study is being done to evaluate the rate of hematological response (complete remission/complete remission with partial hematological recovery [CR/CRh*]) induced by blinatumomab in Chinese adults with relapsed/refractory…
- Trial name
- NCT03476239
- Testing
- Blinatumomab, Dexamthasone
- Where
- 23 sites in China
- Volunteers
- 121 people
- Sponsor
- Amgen
Leukemia, Myeloid, Acute
HDM201 Added to CT in R/R or Newly Diagnosed AML
This is a multi-center open-label Phase I/II study investigating orally administered HDM201 in combination with chemotherapy in two populations: subjects with first line AML or subjects with relapsed/refractory AML.
- Trial name
- NCT03760445
- Testing
- HDM201, cytarabine, anthracycline
- Sponsor
- Novartis Pharmaceuticals
Hodgkin Lymphoma, Adult, Relapsed Hodgkin's Disease, Adult
RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT
This is a multicenter, observational real world study with prospective follow up that will evaluate the treatment approach in patients with relapsed/refractory cHL who undergo ASCT in Argentina.
- Conditions
- Hodgkin Lymphoma, Adult, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma
- Trial name
- NCT04776265
- Testing
- Evaluation of therapeutical approach after ASCT
- Where
- 15 sites in Argentina
- Volunteers
- 100 people
- Sponsor
- Grupo Argentino de Tratamiento de la Leucemia Aguda
Leukemia, Myelodysplastic Syndromes
Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of dolastatin 10 in treating patients who have refractory…
- Trial name
- NCT00003693
- Testing
- Dolastatin 10
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myelodysplastic Syndromes
Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00005593
- Testing
- carboplatin, fludarabine phosphate, topotecan hydrochloride
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Case Comprehensive Cancer Center
Lymphoma
Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00004907
- Testing
- busulfan, cyclophosphamide, etoposide
- Where
- United States
- Sponsor
- Northwestern University
Leukemia
Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have acute…
- Trial name
- NCT00005795
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Northwestern University